GDC 0276

Drug Profile

GDC 0276

Alternative Names: GDC-0276; RG-7893

Latest Information Update: 06 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Xenon Pharmaceuticals
  • Developer Genentech; Xenon Pharmaceuticals
  • Class Non-opioid analgesics; Small molecules
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 24 Feb 2017 Genentech withdraws prior to enrolment a phase I bioavailability trial in Healthy volunteers in United Kingdom (NCT02856152)
  • 08 Jan 2017 Genentech completes a phase I trial in Pain (In volunteers) in Canada (PO)
  • 15 Mar 2016 Xenon Pharmaceuticals and Genentech extends its agreement to co-develop GDC 0276 for Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top